Prof. Dr. Bernd Kasper
University of Heidelberg, Mannheim University Medical Center, Sarcoma Unit, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
20Years (2007-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 March 2020 in European Journal of Cancer
Journal Article
BABen Alman
Ben Alman
SASteven Attia
Steven Attia
CBChristina Baumgarten
Christina Baumgarten
CBCharlotte Benson
Charlotte Benson
JBJean-Yves Blay
Jean-Yves Blay
NZNikolaos Zafiropoulos
Nikolaos Zafiropoulos
+51
Desmoid tumor (DT; other synonymously used terms: Desmoid-type fibromatosis, aggressive fibromatosis) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterised by a variable and often unpredictable clinical course. Previously surgery was the standard primary treatment modality; however, in recent years a paradigm shift towards a more conservative management has been introduced and an effort to harmonise the strategy amongst clinicians has been made. We present herein an evidence-based, joint global consensus guideline approach to the management of this disease focussing on: molecular genetics, indications for an active treatment, and available systemic therapeutic options. This paper follows a one-day consensus meeting held in Milan, Italy, in June 2018 under the auspices of the European Reference Network for rare solid adult cancers, EURACAN, the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) as well as Sarcoma Patients EuroNet (SPAEN) and The Desmoid tumour Research Foundation (DTRF). The meeting brought together over 50 adult and pediatric sarcoma experts from different disciplines, patients and patient advocates from Europe, North America and Japan.
23 June 2017 in Annals of Oncology
Journal Article
Bernd KasperCBC. Baumgarten
C. Baumgarten
JGJ. Garcia
J. Garcia
SBS. Bonvalot
S. Bonvalot
Rick HaasMWM. Wartenberg
M. Wartenberg
+26
Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals’ AND patients’ expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.
28 April 2021 in Cancer
Journal Article
Silvia StacchiottiAFAnna Maria Frezza
Anna Maria Frezza
Jaen-Yves BlayEBElizabeth H. Baldini
Elizabeth H. Baldini
SBSylvie Bonvalot
Sylvie BonvalotATAnnalisa Trama
Annalisa Trama
+51
1 January 2015 in European Journal of Cancer
Journal Article
Bernd KasperCBC. Baumgarten
C. Baumgarten
SBS. Bonvalot
S. Bonvalot
Rick HaasFHF. Haller
F. Haller
AGAlessandro Gronchi
Alessandro Gronchi +3
4 March 2020 in Cancer
Journal Article
LDLorenzo D'Ambrosio
Lorenzo D'AmbrosioNTNathan Touati
Nathan Touati
Jaen-Yves BlayGGGiovanni Grignani
Giovanni GrignaniRFRonan Flippot
Ronan Flippot
TGthe European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
+23
1 May 2017 in European Journal of Cancer
Journal Article
Bernd Kasper
Viktor GruenwaldPRPeter Reichardt
Peter Reichardt
SBSebastian Bauer
Sebastian BauerGRGeraldine Rauch
Geraldine Rauch
PHPeter Hohenberger
Peter Hohenberger
+5
About Me
Prof. Bernd Kasper studied Medicine at the University of Heidelberg and received his MD degree from Heidelberg University in 2000. In 2001, he finalized his thesis at the German Cancer Research Centre (DKFZ) in Heidelberg. In 2007/2008, he specialized in Internal Medicine and Medical Haematology/Oncology at the Department of Internal Medicine V at the University of Heidelberg. Currently, he works at the Sarcoma Unit of the Mannheim Cancer Center (MCC) at the Mannheim University Medical Center, University of Heidelberg. Prof. Kasper has a lifetime professional dedication to patient care and research in soft tissue sarcomas (STS), desmoid-type fibromatosis (DF), and gastrointestinal stromal tumors (GIST). His clinical practice focuses exclusively on these disease entities. He is head of the study center of the German Interdisciplinary Sarcoma Group (GISG) and is active in national and international study groups (AIO, EORTC). He is the Principal Investigator of several national and international trials on STS, DF, and GIST. Currently, he serves as the past Chair of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) and is the Outreach Chair of the Connective Tissue Oncology Society (CTOS). Prof. Kasper has authored around 100 scientific publications. He is dedicated as a board member to patient organizations dealing with STS, DF, and GIST on the national and international level, such as SPAGN, NLMSF, and DTRF.